GlobeNewswire by notified

C.K. McWhorter & McWhorter Foundation Launch Pioneering Earth Ambassador Initiative

Share

MIAMI, March 23, 2024 (GLOBE NEWSWIRE) -- The McWhorter Foundation, a leader in environmental advocacy and education, is excited to announce the launch of its Earth Ambassador Initiative, a bold step forward in the global effort to combat environmental challenges. This innovative program is designed to empower individuals with the knowledge, skills, and resources needed to make a significant impact in their communities and beyond.

“In a time when environmental issues are at the forefront of global concerns, it is more important than ever to take decisive action,” - Chairman of the McWhorter Foundation. “The Earth Ambassador Initiative aims to create a network of informed and active champions for the planet, driving change and promoting sustainability at every level.”

A Comprehensive Approach to Environmental Stewardship

The Earth Ambassador Initiative focuses on several key areas:

  • Biodiversity Protection: Strategies to conserve ecosystems and protect wildlife will be central to the initiative, with programs designed to engage communities in habitat restoration and species conservation.
  • Climate Action: The initiative will promote cutting-edge solutions to reduce carbon footprints, emphasizing renewable energy adoption, sustainable agriculture practices, and conservation efforts.
  • Community Engagement: At the heart of the Earth Ambassador Initiative is the belief that real change starts at the community level. The program will offer training, resources, and support for individuals to lead conservation efforts, organize local projects, and educate others about the importance of environmental stewardship.

Join the Movement

The McWhorter Foundation is calling on individuals passionate about the environment to join the Earth Ambassador Initiative. Participants will have the opportunity to become part of a global movement, gain access to exclusive resources, and lead the charge in making a tangible difference in the health of our planet.

About the McWhorter Foundation

Dedicated to fostering innovative solutions to today’s most pressing environmental issues, the McWhorter Foundation invests in education, conservation, and sustainable development projects around the world. With a focus on empowering individuals and communities, the Foundation is committed to creating a sustainable future for all.

Disclaimer, Disclosure & Legal Notice:
This press release is for informational purposes only and does not constitute legal, financial, or investment advice. It is not intended to provide specific recommendations, endorsements, or investment strategies. The information contained herein is subject to change without notice.

Regulatory Considerations:

This press release is not intended to constitute an offer to sell or the solicitation of an offer to buy securities. Any offers, sales, or purchases will be made in accordance with applicable securities laws and regulations. McWhorter Foundation has not registered with the U.S. Securities and Exchange Commission (SEC) and may operate under exemptions. Any investment decisions should be made in consultation with appropriate legal and financial advisors, considering the individual circumstances and objectives of potential investors.

Forward-Looking Statements:

Forward-looking statements involve inherent risks and uncertainties, and we caution you not to place undue reliance on forward-looking statements. We do not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. Actual results or outcomes may differ materially from those indicated or suggested by any forward-looking statements as a result of various factors, including, but not limited to, regulatory and legal developments, market conditions, and the outcome of negotiations. We disclaim any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/0ea312ad-25e5-40fb-9d50-e7fe98701934

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Convening Notice for Annual General Meeting and Extraordinary General Meeting of Shareholders17.4.2024 02:00:00 CEST | Press release

Convening Notice for Annual General Meeting and Extraordinary General Meeting of Shareholders MILLICOM INTERNATIONAL CELLULAR S.A. Registered Address: 2, Rue du Fort Bourbon L-1249 Luxembourg, Grand Duchy of Luxembourg – R.C.S. Luxembourg: B 40.630 – I. NOTICE The annual general meeting (“AGM”) and subsequent extraordinary general meeting (“EGM”) of the shareholders of MILLICOM INTERNATIONAL CELLULAR S.A. (“Millicom” or the “Company”) is hereby convened to be held at Hotel Le Royal, 12 Bd Royal, 2449 Luxembourg on Thursday, May 23, 2024, at 11:00 a.m. Central European Time ("CET"). To attend the AGM and EGM or vote by proxy, please follow the instructions in section IV: “Right to participate at the AGM and the EGM”. The AGM and EGM will consider and vote on the agenda points listed below. Please refer to section IX: “Notes to the Agenda Points of the AGM and EGM” to find detailed information about these proposals. II. AGENDA AGM To elect the chair of the AGM and to empower the chair of

Millicom’s Nomination Committee’s proposal for Board of Directors17.4.2024 02:00:00 CEST | Press release

Millicom’s Nomination Committee’s proposal for Board of Directors Luxembourg, April 17, 2024 – In advance of the Annual General Meeting of shareholders (“AGM”) of Millicom International Cellular S.A. (“Millicom”), to be held on May 23, 2024, Millicom’s Nomination Committee proposes: The election of Maxime Lombardini and Justine Dimovic as new Directors of the Board; The re-election of María Teresa Arnal Machado, Bruce Churchill, Aude Durand, Tomas Eliasson, Mauricio Ramos, Thomas Reynaud, and Blanca Treviño de Vega as Directors of the Board; and the election of Mauricio Ramos as Chair of the Board. Pernille Erenbjerg and Michael Golan have decided not to seek re-election. Maxime Lombardini will bring his extensive experience and track record in leading businesses in the telecommunications industry, as well as the strong knowledge of Millicom that he has gained while serving as President and Chief Operating Officer since September 2023. Justine Dimovic will bring a wealth of capital all

Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)16.4.2024 23:30:00 CEST | Press release

SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva SELARSDI is expected to be marketed in the U.S. on or after February 21, 2025, following a settlement agreement with Johnson & Johnson, the manufacturer of StelaraSELARSDI was developed and is manufactured by Alvotech using murine cell (Sp2/0) and a continuous perfusion process, which are the same type of cells and process used for the production of Stelara REYKJAVIK, ICELAND & PARSIPPANY, NJ — Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved SELARSDI (ustekinumab-aekn) injection for subcutaneous use, as a biosimilar to Stelara®, for the treatment of moderate to severe plaque psoriasis and for active psoriatic arthritis in adults and pediatric patients 6 years and older. Unde

Atico Reports Consolidated Financial Results for 202316.4.2024 22:30:29 CEST | Press release

(All amounts expressed in US dollars, unless otherwise stated) VANCOUVER, British Columbia, April 16, 2024 (GLOBE NEWSWIRE) -- Atico Mining Corporation (the “Company” or “Atico”) (TSX.V: ATY | OTC: ATCMF) today announced its financial results for the year ended December 31, 2023, posting income from mining operations of $7.4 million and a net loss of $5.8 million. Production for the year at Atico’s El Roble mine totaled 13.2 million pounds (“lbs”) of copper and 10,149 ounces (“oz”) of gold in concentrate at a cash cost(1) of $2.04 per payable pound of copper(2). Fernando E. Ganoza, CEO and Director, commented, "we had a challenging year overall, with the first half of the year facing lower than expected head grades and lower throughput due to mechanical and operational issues, coupled with a significant appreciation in the Colombian Peso throughout the year which materially increased our costs. Despite these challenges the team did a great job getting El Roble mine back on track in the

Ultimovacs Implements Operational Adjustments to Support Continuous Advancement of the UV1 Vaccine Phase II Program16.4.2024 22:10:00 CEST | Press release

Due to the broad diversity in the UV1 Phase II program and the encouraging results from previous UV1 trials, Ultimovacs remain confident in UV1’s potential and are strongly committed to bringing the company across the next important data points: The readout from FOCUS in Q3 2024 and DOVACC results in H1 2025Activity level adjustments and operational prioritization are implemented to sustain the financial runway, including a workforce reduction of approximately 40% The operational adjustment plan extends the anticipated cash runway to the fourth quarter of 2025, through the readout from the Phase II DOVACC trial Oslo, April 16, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announces a plan to optimize its business operations to support the continuous advancement of UV1 and long-term business growth. “We remain dedicated to our investigation of the potential impact of UV1 vaccine across several c

HiddenA line styled icon from Orion Icon Library.Eye